STAT+: Novo Nordisk stops two cardiovascular trials of drug aimed at lowering inflammation
Novo Nordisk has stopped two trials of a drug that aims to tame inflammation as a way to improve cardiovascular health, another blow for the approach.
STAT
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from STAT.
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
STAT (www.statnews.com), a Tier B publisher, filed this report on . CurrentWire published this page 16 minutes later, on .
Signal breakdown
CurrentWire ranked this story 61.8 of 100 in the snapshot this page was rendered from.
- Freshness
- 32.3 of 35
- Source authority
- 14 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 3.5 of 10
- Story prominence
- 8 of 10
- Velocity
- 0 of 5
Strongest signal: freshness, 32.3 of 35. How each signal is calculated.
Filed under Health · International · News. Topics extracted from this report, with other live CurrentWire stories mentioning each: Novo Nordisk (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.